Regarding the role of inflammation in progression of diabetes this study was conducted to investigate the association between inflammatory biomarkers such as nitric oxide (NO), tumor necrosis factor alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP) with the chance of existence of diabetic retinopathy and its progression in patients with diabetes.
A total of 83 patients with T2DM (Type 2 diabetes mellitus) were divided into three groups of patients with proliferative diabetic retinopathy (PDR), patients with non-proliferative diabetic retinopathy (NPDR) and patients without diabetic retinopathy (NDR) based on ophthalmologic funduscopic examination. Twenty six healthy controls were also enrolled. Blood samples were taken after 12 h of overnight fasting, NO, TNF-α, and hs-CRP were measured. Association of the level of these biomarkers with retinopathy was analyzed.
The levels of TNF-α, NO and hs-CRP were higher among patients with diabetic retinopathy. Multinomial Logistic Regression model showed that TNF-α and NO could predict the presence of retinopathy among patients with diabetes when adjusted for hs-CRP, HbA1c, FBS, gender, total cholesterol, triglyceride, HDL, LDL, BMI, and age (respectively OR = 1.76, CI 95% = 1.01–3.02, p = 0.046 and OR = 1.12, CI 95% = 1.05–1.18, p < 0.001); however they could not predict the severity of retinopathy. In ROC analysis AUC for TNFα was 0.849 (p < 0.001) and for NO was 0.907 (p < 0.001). Serum TNF-α level of 7.10 pmol/L could be suggestive of the presence of retinopathy (sensitivity = 92.2% and specificity = 66.0%), also serum NO level of 45.96 μmol/L could be suggestive of the presence of retinopathy (sensitivity = 96.1% and specificity = 86%).
Our results suggest elevated levels of NO and TNF-α can be suggestive of diabetic retinopathy.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Y. Behl et al. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am. J. Pathol. 172(5), 1411–1418 (2008)
M.V. van Hecke et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 48(7), 1300–1306 (2005)
A.M. Spijkerman et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabet Med. 24(9), 969–976 (2007)
T.S. Kern, Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 95103 (2007)
K. Zorena et al. Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Med. Inflamm. 2007, 92196–92196 (2007)
D. Ray et al. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 53(3), 861 (2004)
A.M. Joussen et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 16(3), 438–440 (2002)
R. Arita et al. A key role for ROCK in TNF-α–mediated diabetic microvascular damage. Investig. Ophthalmol. Vis. Sci. 54(3), 2373–2383 (2013)
M. Torzewski et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20(9), 2094–2099 (2000)
A.R. Tall, C-reactive protein reassessed. N. Engl. J. Med. 350(14), 1450–1452 (2004)
J. Song et al. Relationship between C-reactive protein level and diabetic retinopathy: a systematic review and meta-analysis. PLoS ONE 10(12), e0144406 (2015)
W. Zhang et al. Anti-inflammatory therapy for diabetic retinopathy. Immunotherapy 3(5), 609–628 (2011)
Q. Li et al. Diabetic eNOS-knockout mice develop accelerated retinopathy. Investig. Ophthalmol. Vis. Sci. 51(10), 5240–5246 (2010)
A.M. Abu El-Asrar et al. Inducible nitric oxide synthase and vascular endothelial growth factor are colocalized in the retinas of human subjects with diabetes. Eye 18(3), 306–313 (2004)
G.K. Kolluru, S.C. Bir, C.G. Kevil, Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int. J. Vasc. Med. 2012, 30 (2012)
American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes. Diabetes Care, 42(Supplement 1), S13 (2019)
G.S. Hotamisligil, B.M. Spiegelman, Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43(11), 1271–1278 (1994)
G.S. Hotamisligil et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Investig. 95(5), 2409–2415 (1995)
P.A. Kern et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Investig. 95(5), 2111–2119 (1995)
P. Peraldi et al. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J. Biol. Chem. 271(22), 13018–13022 (1996)
F. Balkwill, TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25(3), 409–416 (2006)
M.J. Tisdale, Cancer cachexia. Langenbecks Arch. Surg. 389(4), 299–305. (2004)
A.M. Joussen et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 15, 1418–1428 (2009)
S. Doganay et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16(2), 163–170 (2002)
N. Makino et al. High serum TNF-α level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J. Diabetes Complicat. 19(6), 347–355 (2005)
D.N. Koleva-Georgieva, N.P. Sivkova, D. Terzieva, Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med. 53(2), 44–50 (2011)
H. Kaneto et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes 44(7), 733–738 (1995)
M.L. McDaniel et al. Cytokines and nitric oxide in islet inflammation and diabetes. Proc. Soc. Exp. Biol. Med. 211(1), 24–32 (1996)
T.J. Guzik, R. Korbut, T. Adamek-Guzik, Nitric oxide and superoxide in inflammation and immune regulation. J. Physiol. Pharmacol. 54(4), 469–487 (2003)
Z. Davoudi et al. Changing correlations among ADMA, NO and hs-CRP in normoalbuminuric and microalbuminuric patients with type 2 diabetes. Meta Gene 10, 95–99 (2016)
J.L. Wilkinson-Berka, Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr. Pharm. Des. 10(27), 3331–3348 (2004)
E.C. Leal et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 48(11), 5257–5265 (2007)
P.S. Chan, M. Kanwar, R.A. Kowluru, Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J. Diabetes Complicat. 24(1), 55–63 (2010)
M. Manju et al. Relationship between glycosylated hemoglobin, serum nitric oxide and mean arterial blood pressure. Int. J. Biomed. Sci. 10(4), 252–257 (2014)
A. Ghosh et al. Serum nitric oxide status in patients with type 2 diabetes mellitus in Sikkim. Int. J. Appl. Basic Med. Res. 1(1), 31–35 (2011)
D. Tousoulis et al. The role of nitric oxide on endothelial function. Curr. Vasc. Pharmacol. 10(1), 4–18 (2012)
A.M. El-Asrar, Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr. J. Ophthalmol. 19(1), 70–74 (2012)
T.S. Assmann et al. Nitric oxide levels in patients with diabetes mellitus: a systematic review and meta-analysis. Nitric Oxide 61, 1–9 (2016)
A.N.N. Mertens, P. Holvoet, Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 15(12), 2073–2084 (2001)
Research is reported in this publication was supported by Elite Researcher Grant Committee under award number 963276 from the National Institutes for Medical Research Development (NIMAD), Tehran, Iran.
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Khaloo, P., Qahremani, R., Rabizadeh, S. et al. Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c. Endocrine (2020). https://doi.org/10.1007/s12020-020-02353-x
- Diabetic retinopathy
- Type 2 diabetes
- Nitric oxide
- Tumor necrosis factor alpha
- High-sensitivity C-reactive protein